Barclays Bolsters Healthcare Investment Banking: Inside the Major Executive Reshuffle

Barclays is making significant moves to strengthen its footprint in the healthcare finance sector, unveiling a slate of high-profile leadership changes across investment banking and research divisions. The reshuffling includes new Co-Heads for Healthcare M&A operations, expanded coverage in healthcare technology banking, and a new lead for digital health equity research—signaling the bank’s intensified commitment to this lucrative sector.

Dual Leadership at Healthcare M&A

The bank has named Maneet Singh and Evan Matlin as joint heads of its Healthcare M&A practice in the United States. Singh, bringing extensive sector expertise from prior roles at Goldman Sachs and Credit Suisse, teams up with Matlin, a veteran of the unit who previously led EMEA healthcare M&A efforts from Barclays’ London office. Together, they’ll oversee the firm’s advisory work across the entire healthcare landscape and report directly to Americas M&A Co-Heads Dan Grabos and Larry Hamdan from their New York base.

The partnership emphasizes Barclays’ strategy to deepen client relationships while expanding its M&A and capital markets offerings within healthcare. This dual appointment reflects confidence in both leaders’ ability to navigate complex cross-border transactions and manage senior deal teams—critical skills in an increasingly competitive advisory space.

Technology-Driven Healthcare Banking Gets a Boost

The bank is also welcoming Jon Swope to its Healthcare Information Technology Banking team as a Managing Director. Reporting to Global Head of Healthcare Banking Rick Landgarten, Swope arrives from SVB Securities where he established and led their Digital Health and HealthTech practice.

His hire underscores a broader industry trend: technology is reshaping healthcare delivery, from clinical outcomes to payments infrastructure and value-based care models. By adding depth to its healthcare technology coverage, Barclays is positioning itself to capture advisory mandates in this rapidly evolving subsector.

Building Out Research Capabilities

Separately, Barclays Research has appointed Stephanie Davis as a Managing Director to lead U.S. equity research on Healthcare Technology & Digital Health. Davis, ranked among the top analysts by Institutional Investor in 2022, transitions from SVB Securities where she managed their healthcare technology research franchise. She’ll report to Rob Rouse, Head of Americas Equity Research.

The Broader Healthcare Push

These appointments follow a series of recent hires, including Jeff Ammerman as Global Head of Specialty Pharmaceuticals Investment Banking, alongside Managing Directors Amit Tyagi and John Hagens focused on healthcare tools, diagnostics, and medical technology respectively. Jim Birchenough chairs Global Healthcare Investment Banking while co-heading Global Biopharma, working alongside Alexis de Rosnay in a complementary leadership structure.

The moves reflect Barclays’ determination to expand healthcare coverage across both U.S. and European markets, leveraging its integrated banking and research capabilities to strengthen client relationships and capture market share in a sector that continues to attract significant M&A activity and capital deployment.